ROBERT J. LEFKOWITZ, M.D. - Corporate Board Profile

LEXICON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2008-03-14	Robert J. Lefkowitz, M.D. has been a director since February 2001 ... The current members of the corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. ... The following table presents summary information for the year ended December 31, 2007 regarding the compensation of the non-employee members of our board of directors. ... Robert J. Lefkowitz, M.D. $28,500 Fees Earned or Paid in Cash, $31,588 Option Awards, $50,000 All Other Compensation, Total $110,088.
2009-03-13	The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Mr. Debbane, Dr. Lefkowitz and Dr. Swain are “independent” in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc.
2010-03-19	The following table presents summary information for the year ended December 31, 2009 regarding the compensation of the non-employee members of our board of directors. Samuel L. Barker, Ph.D. $48,500 $14,946 — $63,446 Philippe J. Amouyal $30,500 $7,473 — $37,973 Raymond Debbane $32,000 $7,473 — $39,473 Robert J. Lefkowitz, M.D. $28,500 $7,473 $50,000 (4) $85,973 Alan S. Nies, M.D. $30,000 $7,473 $75,000 (5) $112,473 Frank P. Palantoni $37,000 $7,473 — $44,473 Christopher J. Sobecki $27,000 $7,473 — $34,473 Judith L. Swain, M.D. $29,500 $7,473 — $36,973 Kathleen M. Wiltsey $28,000 $7,473 — $35,473
2012-03-16	Robert J. Lefkowitz, M.D. has been a director since February 2001 and a consultant to our company since March 2003. Dr. Lefkowitz provides us with the benefit of his medical expertise and his extensive experience in biological and pharmaceutical research.
2013-03-25	Robert J. Lefkowitz, M.D. has been a director since February 2001 and a consultant to our company since March 2003. ... Dr. Lefkowitz is a member of the National Academy of Sciences and has received more than 50 major awards for his research, including the 2012 Nobel Prize in Chemistry. ... The following table presents summary information for the year ended December 31, 2012 regarding the compensation of the non-employee members of our board of directors. ... Robert J. Lefkowitz, M.D. $28,000 Fees Earned or Paid in Cash, $25,922 Option Awards, $19,999 Restricted Stock Awards, $50,000 All Other Compensation for consulting services, Total $123,921.
2014-03-14	The following table presents summary information for the year ended December 31, 2013 regarding the compensation of the non-employee members of our board of directors. Name: Robert J. Lefkowitz, M.D. Fees Earned or Paid in Cash: $28,000 Option Awards: $30,074 Restricted Stock Awards: $20,000 All Other Compensation: $50,000 Total: $128,074
2015-03-13	Robert J. Lefkowitz, M.D. has been a director since February 2001 and a consultant to our company since March 2003. Corporate Governance Committee member. Director compensation table shows $123,965 total compensation in 2014, including consulting fees.
2016-03-18	Robert J. Lefkowitz, M.D. has been a director since February 2001 ... The current members of our corporate governance committee are ... Robert J. Lefkowitz, M.D. ... Director Compensation in 2015 ... Robert J. Lefkowitz, M.D. $113,363
2017-03-17	The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Mr. Debbane, Dr. Lefkowitz and Dr. Swain are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. ... Director Compensation in 2016 ... Robert J. Lefkowitz, M.D. ... $127,207 ...
2018-03-16	Robert J. Lefkowitz, M.D. has been a director since February 2001 and a consultant to our company since March 2003. Dr. Lefkowitz provides us with the benefit of his medical expertise. The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Dr. Lefkowitz is “independent” in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. The following table presents summary information for the year ended December 31, 2017 regarding the compensation of the non-employee members of our board of directors. Robert J. Lefkowitz, M.D. received total compensation of $126,924 in 2017.
2019-03-15	Robert J. Lefkowitz, M.D. has been a director since February 2001. ... The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. ... The following table presents summary information for the year ended December 31, 2018 regarding the compensation of the non-employee members of our board of directors. ... Robert J. Lefkowitz, M.D. $28,000 Fees Earned or Paid in Cash, $14,888 Option Awards, $19,999 Restricted Stock Awards, $33,333 All Other Compensation, Total $96,220.
2020-03-13	Robert J. Lefkowitz, M.D. has been a director since February 2001. ... The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. ... The following table presents summary information for the year ended December 31, 2019 regarding the compensation of the non-employee members of our board of directors. ... Robert J. Lefkowitz, M.D. $44,643 Fees Earned or Paid in Cash, $24,460 Option Awards, $19,652 Restricted Stock Unit Awards, Total $88,755.
2021-03-19	Robert J. Lefkowitz, M.D. has been a director since February 2001. The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D.
2022-04-08	Robert J. Lefkowitz, M.D. has been a director since February 2001. Dr. Lefkowitz is the James B. Duke Professor of Medicine, professor of biochemistry and a Howard Hughes Medical Institute investigator at Duke University Medical Center, where he has served on the faculty since 1973. Dr. Lefkowitz is a member of the National Academy of Sciences and has received more than 50 major awards for his research, including the 2012 Nobel Prize in Chemistry, the Shaw Prize, the Albany Medical Center Prize and the 2007 National Medal of Science. Dr. Lefkowitz received his B.A. from Columbia University and his M.D. from Columbia University College of Physicians and Surgeons. Dr. Lefkowitz provides us with the benefit of his medical expertise and his extensive experience in biological and pharmaceutical research, particularly with respect to the identification of drug targets and preclinical evaluation of drug candidates, gained in more than 40 years as a member of the faculty at Duke University Medical Center. Director Compensation in 2021: $95,621.
2023-03-17	The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Mr. Debbane, Dr. Lefkowitz and Dr. Swain are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. ... The following table presents summary information for the year ended December 31, 2022 regarding the compensation of the non-employee members of our board of directors. ... Robert J. Lefkowitz, M.D. $50,000 Fees Earned or Paid in Cash, $20,387 Option Awards, $16,465 Restricted Stock Unit Awards, Total $86,852.
2024-03-26	Robert J. Lefkowitz, M.D. has been a director since February 2001. Dr. Lefkowitz provides us with the benefit of his medical expertise. The current members of our corporate governance committee are Raymond Debbane (chair), Robert J. Lefkowitz, M.D. and Judith L. Swain, M.D. The following table presents summary information for the year ended December 31, 2023 regarding the compensation of the non-employee members of our board of directors. Robert J. Lefkowitz, M.D. received $52,133 in fees and $42,824 in stock awards in 2023, totaling $94,957.